Verve Therapeutics Acquisition Marks New Chapter in Gene Editing

Verve Therapeutics US92539P1012

The independent journey of Verve Therapeutics on public markets concluded on July 25, 2025, when the biotechnology firm was officially delisted from the Nasdaq. This move resulted from its comprehensive acquisition by pharmaceutical leader Eli Lilly, terminating Verve’s status as a publicly traded entity.

Eli Lilly secured ownership of all outstanding Verve shares through a transaction valuing each share at up to $13.50. The arrangement includes an immediate cash payment of $10.50 per share, supplemented by a contingent value right potentially delivering an additional $3.00 per share. With the total deal value potentially reaching $1.3 billion, this acquisition represents a significant consolidation within the biopharmaceutical sector.

Revolutionary Cardiovascular Treatment Drives Interest